JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 149 USD | +0.15% |
|
+3.02% | -4.97% |
| May. 07 | Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs | RE |
| May. 06 | J&J: encouraging results in prostate cancer | CF |
Presenter SpeechTerence Flynn (Analysts)Thanks for joining us, everybody. I'm Terence Flynn, a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
148.7
USD
Average target price
173.3
USD
Spread / Average Target
+16.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.97% | 358B | |
| +32.95% | 700B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B | |
| +3.70% | 124B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Transcript : Johnson & Johnson Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10